FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898092643> ?p ?o ?g. }

• W2898092643 endingPage "2253" @default.
• W2898092643 startingPage "2247" @default.
• W2898092643 abstract "Head and neck cancer (HNC) has a poor prognosis at advanced stages. Given the immunosuppressive tumor microenvironment in HNC, inhibition of the programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling pathway represents a promising therapeutic approach. Atezolizumab (anti-PD-L1) is efficacious against many tumor types. Here we report the clinical safety and activity from the HNC cohort of the phase Ia PCD4989g clinical trial.Patients with previously treated, advanced HNC received atezolizumab i.v. every 3 weeks for 16 cycles, up to 1 year or until loss of clinical benefit. Patients were monitored for safety and tolerability and evaluated for response at least every 6 weeks. Baseline PD-L1 expression level and human papillomavirus (HPV) status were evaluated.Thirty-two patients were enrolled; 7 patients (22%) had a primary tumor in the oral cavity, 18 (56%) in the oropharynx, 1 (3%) in the hypopharynx, 2 (6%) in the larynx, and 4 (13%) in the nasopharynx. Seventeen patients (53%) had ≥2 prior lines of therapy. Twenty-one patients (66%) experienced a treatment-related adverse event (TRAE), with three experiencing grade 3 TRAEs and one experiencing a grade 4 TRAE (per CTCAE v4.0). No grade 5 TRAEs were reported. Objective responses by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) occurred in 22% of patients, with a median duration of response of 7.4 months (range 2.8-45.8 months). Median progression-free survival was 2.6 months (range 0.5-48.4 months), and median overall survival was 6.0 months (range 0.5-51.6+ months). Responses showed no association with HPV status or PD-L1 expression level.In this heavily pre-treated advanced HNC cohort, atezolizumab had a tolerable safety profile and encouraging activity, with responses observed regardless of HPV status and PD-L1 expression level. These findings warrant further investigation of atezolizumab in HNC. ClinicalTrials.gov number: NCT01375842." @default.
• W2898092643 created "2018-11-02" @default.
• W2898092643 creator A5005597325 @default.
• W2898092643 creator A5006496749 @default.
• W2898092643 creator A5009078484 @default.
• W2898092643 creator A5041365902 @default.
• W2898092643 creator A5045670207 @default.
• W2898092643 creator A5052730435 @default.
• W2898092643 creator A5056037326 @default.
• W2898092643 creator A5069613777 @default.
• W2898092643 creator A5076494122 @default.
• W2898092643 creator A5079422406 @default.
• W2898092643 creator A5086994520 @default.
• W2898092643 creator A5090977453 @default.
• W2898092643 creator A5091123338 @default.
• W2898092643 date "2018-11-01" @default.
• W2898092643 modified "2023-10-15" @default.
• W2898092643 title "Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial" @default.
• W2898092643 cites W1968017437 @default.
• W2898092643 cites W1971208896 @default.
• W2898092643 cites W2019607817 @default.
• W2898092643 cites W2088302608 @default.
• W2898092643 cites W2095043719 @default.
• W2898092643 cites W2110664940 @default.
• W2898092643 cites W2112845420 @default.
• W2898092643 cites W2122495232 @default.
• W2898092643 cites W2124427232 @default.
• W2898092643 cites W2125770688 @default.
• W2898092643 cites W2127605299 @default.
• W2898092643 cites W2146530741 @default.
• W2898092643 cites W2401455386 @default.
• W2898092643 cites W2528245131 @default.
• W2898092643 cites W2529484692 @default.
• W2898092643 cites W2560322684 @default.
• W2898092643 cites W2567564314 @default.
• W2898092643 cites W2569525507 @default.
• W2898092643 cites W2588574345 @default.
• W2898092643 cites W2734674679 @default.
• W2898092643 cites W2747272999 @default.
• W2898092643 cites W2753803220 @default.
• W2898092643 doi "https://doi.org/10.1093/annonc/mdy411" @default.
• W2898092643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30219915" @default.
• W2898092643 hasPublicationYear "2018" @default.
• W2898092643 type Work @default.
• W2898092643 sameAs 2898092643 @default.
• W2898092643 citedByCount "95" @default.
• W2898092643 countsByYear W28980926432019 @default.
• W2898092643 countsByYear W28980926432020 @default.
• W2898092643 countsByYear W28980926432021 @default.
• W2898092643 countsByYear W28980926432022 @default.
• W2898092643 countsByYear W28980926432023 @default.
• W2898092643 crossrefType "journal-article" @default.
• W2898092643 hasAuthorship W2898092643A5005597325 @default.
• W2898092643 hasAuthorship W2898092643A5006496749 @default.
• W2898092643 hasAuthorship W2898092643A5009078484 @default.
• W2898092643 hasAuthorship W2898092643A5041365902 @default.
• W2898092643 hasAuthorship W2898092643A5045670207 @default.
• W2898092643 hasAuthorship W2898092643A5052730435 @default.
• W2898092643 hasAuthorship W2898092643A5056037326 @default.
• W2898092643 hasAuthorship W2898092643A5069613777 @default.
• W2898092643 hasAuthorship W2898092643A5076494122 @default.
• W2898092643 hasAuthorship W2898092643A5079422406 @default.
• W2898092643 hasAuthorship W2898092643A5086994520 @default.
• W2898092643 hasAuthorship W2898092643A5090977453 @default.
• W2898092643 hasAuthorship W2898092643A5091123338 @default.
• W2898092643 hasBestOaLocation W28980926431 @default.
• W2898092643 hasConcept C121608353 @default.
• W2898092643 hasConcept C126322002 @default.
• W2898092643 hasConcept C141071460 @default.
• W2898092643 hasConcept C143998085 @default.
• W2898092643 hasConcept C197934379 @default.
• W2898092643 hasConcept C2775949291 @default.
• W2898092643 hasConcept C2776530083 @default.
• W2898092643 hasConcept C2777701055 @default.
• W2898092643 hasConcept C2778375690 @default.
• W2898092643 hasConcept C2779984678 @default.
• W2898092643 hasConcept C2780057760 @default.
• W2898092643 hasConcept C2780474809 @default.
• W2898092643 hasConcept C31760486 @default.
• W2898092643 hasConcept C535046627 @default.
• W2898092643 hasConcept C71924100 @default.
• W2898092643 hasConceptScore W2898092643C121608353 @default.
• W2898092643 hasConceptScore W2898092643C126322002 @default.
• W2898092643 hasConceptScore W2898092643C141071460 @default.
• W2898092643 hasConceptScore W2898092643C143998085 @default.
• W2898092643 hasConceptScore W2898092643C197934379 @default.
• W2898092643 hasConceptScore W2898092643C2775949291 @default.
• W2898092643 hasConceptScore W2898092643C2776530083 @default.
• W2898092643 hasConceptScore W2898092643C2777701055 @default.
• W2898092643 hasConceptScore W2898092643C2778375690 @default.
• W2898092643 hasConceptScore W2898092643C2779984678 @default.
• W2898092643 hasConceptScore W2898092643C2780057760 @default.
• W2898092643 hasConceptScore W2898092643C2780474809 @default.
• W2898092643 hasConceptScore W2898092643C31760486 @default.
• W2898092643 hasConceptScore W2898092643C535046627 @default.
• W2898092643 hasConceptScore W2898092643C71924100 @default.
• W2898092643 hasFunder F4320307115 @default.
• W2898092643 hasFunder F4320307770 @default.

• next